Russ Conroy is an Assistant Editor for CancerNetwork. He specializes in medicine and healthcare, focusing on topics such as oncology, hematology, immunotherapy, and medical technology innovations. Russ's work has been featured in prominent publications including AJMC - The American Journal of Managed Care, Dermatology Times, and Oncology Nursing News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Russ Conroy's articles primarily focus on healthcare and pharmaceutical topics, with a significant emphasis on citing data to support the information provided. Given this approach, Russ would likely be interested in pitches that provide access to new or exclusive scientific research findings related to cancer treatment, leukemia, breast cancer, multiple myeloma, and immunotherapy.
Since Russ focuses heavily on citing data and presenting evidence-based information in his articles, he may be particularly responsive to pitches from experts who can provide insights based on the latest clinical trials or research studies within the field of oncology and cancer treatment. Additionally, sources who can offer contextualized expert commentary supported by robust scientific evidence could capture his interest.
While there is no specific geographic focus mentioned for Russ Conroy’s coverage attributes or article titles provided here; it appears that he covers a broad range of international developments in healthcare and pharmaceuticals without being limited to any particular region.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Russ Conroy
The role of adjuvant immunotherapy remains unclear in this NSCLC population following data from the phase 3 ALCHEMIST trial.
By: Russ Conroy
A matching-adjusted indirect comparison highlighted linvoseltamab as a potentially effective treatment option for those with triple-class–exposed disease.
The nilotinib tablets may support patients who have difficulty swallowing while offering flexibility to take treatment with or without water.
More than 90% of patients achieved a composite complete response to azacitidine plus venetoclax and ivosidenib in a phase 1b/2 trial.
By: Russ Conroy
The ivonescimab-based regimen appeared effective in both platinum-sensitive and platinum-resistant cohorts in a phase 2 study.
By: Russ Conroy
Retrospective data also showed that immune-related toxicities were more common with BCMA CAR T-cell therapy compared with teclistamab.
By: Russ Conroy
Real-world data support prospective evaluation of a frontline venetoclax-based regimen in the second line and beyond.
By: Russ Conroy
Cancer-related survival was similar among patients with PD-L1–positive or PD-L1–negative NSCLC who received durvalumab.
By: Russ Conroy
Data from the phase 3 DeLLphi-304 trial support the European Commission's approval of tarlatamab in extensive-stage small cell lung cancer.
By: Russ Conroy
A recommendation from the external data monitoring committee led to the discontinuation of the phase 3 KEYNOTE-D46/EVOKE-03 study.
